亚洲免费女色在线,久久综合给合久久狠狠狠…,亚洲一区二区成人,免费人成网555www

       首頁(yè) >> 資源庫 >> 中文 >> 專(zhuān)家人才

    專(zhuān)家人才

    • 姓名: 許永
    • 性別: 男
    • 職稱(chēng): 研究員
    • 學(xué)歷: 博士
    • 電話(huà): 020-32093612
    • 傳真: 
    • 電子郵件: xu_yong@gibh.ac.cn
    • 通訊地址 廣州市開(kāi)源大道190號

      簡(jiǎn)歷:

    • 2001.9-2004.7 中國科學(xué)院上海藥物研究所,藥物發(fā)現與設計中心,有機化學(xué),博士;

      2004.8-2006.5 中國科學(xué)院上海有機化學(xué)研究所,生命有機國家重點(diǎn)實(shí)驗室,計算生物學(xué),博士后

      2006.6-2011.8 美國文安諾研究所(Van Andel Institute),結構生物學(xué)與藥物發(fā)現中心,計算與結構生物學(xué),博士后

      2011.9-        中國科學(xué)院廣州生物醫藥與健康研究院,研究員,課題組長(cháng),博士生導師,化學(xué)生物學(xué)與藥物研究中心主任(2021年起)

      2016-      廣東省生物醫藥計算重點(diǎn)實(shí)驗室,副主任

      研究領(lǐng)域:

    • 綜合運用藥物分子設計、藥物化學(xué)、結構生物學(xué)、計算生物學(xué)和藥理學(xué)等多學(xué)科交叉策略,開(kāi)展針對惡性腫瘤等疾病的新藥物靶標發(fā)現與確證、藥物作用機制研究以及創(chuàng )新藥物開(kāi)發(fā)研究。

      承擔科研項目情況:

    • 科技部國家重點(diǎn)研發(fā)計劃(2020年,2016年,2013年);基金委面上項目;中國科學(xué)院科技服務(wù)網(wǎng)絡(luò )計劃(STS計劃)區域重點(diǎn)項目;中科院個(gè)性化藥物戰略性先導科技專(zhuān)項(A類(lèi))等

      社會(huì )任職:

    • 2016- 廣東省生物醫藥計算重點(diǎn)實(shí)驗室,副主任

      2013- 廣東省高性能計算學(xué)會(huì ),副理事長(cháng)

      2015- 廣東省藥學(xué)會(huì )藥物化學(xué)專(zhuān)業(yè)委員會(huì )委員

      獲獎及榮譽(yù):

    • 2020 國務(wù)院特殊津貼

      2018 廣東省自然科學(xué)獎二等獎 (第一完成人)

      2016 美國前列腺癌基金會(huì )挑戰獎

      代表論著(zhù):

    • 累計在Nat Med、Cell Res、Nat Struct Mol Biol、J Med Chem等雜志上發(fā)表SCI論文80余篇,申請專(zhuān)利22項,獲授權8項。

      1. Qiu Li#, Benqiang Yao#, Shiting Zhao, Zhou Lu, Yan Zhang, Qiuping Xiang, Xishan Wu, Haonan Yu, Cheng Zhang, Junhua Li, Xiaoxi Zhuang, Donghai Wu, Yong Li, Yong Xu. Discovery of a Highly Selective and H435R Sensitive Thyroid Hormone Receptor Agonist.

      J Med Chem. 2022 May 4. Doi: 10.1021/acs.jmedchem.2c00144.

      2. Li J#, Zhang C#, Xu H, Wang C, Dong R, Shen H, Zhuang X, Chen X, Li Q, Lu J, Zhang M, Wu X, Loomes KM, Zhou Y, Zhang Y, Liu J, Xu Y. Structure- Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.

      J Med Chem.2022, 65, 5760-5799.

      3. Xiang Q, Wang C, Wu T, Zhang C, Hu Q, Luo G, Hu J, Zhuang X, Zou L, Shen H, Wu X, Zhang Y, Kong X, Liu J, Xu Y. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

      J Med Chem. 2022, 65, 785-810

      4. Wu X#, Shen H#, Zhang Y#, Wang C, Li Q, Zhang C, Zhuang X, Li C, Shi Y, Xing Y, Xiang Q, Wu D, Liu J, Xu Y*. Discovery and characterization of benzimidazole derivative XY123 as a selective, and orally available ROR inverse agonist.

      J Med Chem. 2021, 64, 8775-8797

      5. Wu X, Zhang Y, Xu Y*. Discovery of the First Low Nanomolar Liver Receptor Homolog-1 (LRH-1) Agonist.

        J Med Chem. 2019, 62, 11019-11021

      6. Zhang Y#, Wu X#, Xue X#, Li C, Wang J, Wang R, Zhang C, Wang C, Shi Y, Zou L, Li Q, Huang Z, Hao X, Loomes K, Wu D, Chen HW, Xu J, Xu Y*. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.

        J Med Chem. 2019, 62, 4716-4730

      7. Zhang M#, Zhang Y#, Song M#, Xue X, Wang J, Wang C, Zhang C, Li C, Xiang Q, Wu X, Wu C, Dong B, Xue We, Zhou Y, Chen H, Wu D, Ding K, Xu Y*. Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors as Potential Treatment for Castration-Resistant Prostate Cancer (CRPC).

           J Med Chem, 2018. 61, 3037-3058

      8. Wang, J.; Zou, J.X.; Xue, X.; Cai, D.; Zhang, Y.; Duan, Z.; Xiang, Q.; Yang, J.C.; Louie, M.C.; Borowsky, A.D.; Gao, A.C,; Evans, C.P.; Lam, K.S.; Xu, J.; Kung, H.J.; Evans, R.M.; Xu, Y.*; Chen, H.W.*; ROR- drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer.

         Nat Med, 2016, 22: 488-496.

      9. Xue, X#.; Zhang, Y#.; Liu, Z#.; Song, M.; Xing, Y.; Xiang, Q.; Wang, Z.; Tu, Z.; Zhou, Y.; Ding, K.; Xu Y*. Discovery of benzo[cd]indol-2(1H)-ones as potent and specific BET bromodomain inhibitors: structure-based virtual screening, optimization, and biological evaluation.

         J Med Chem, 2016, 59, 1565-1579

      10.Cao, M.; Liu, X.; Zhang, Y.; Xue, X.; Zhou, X. E.; Melcher, K.; Gao, P.; Wang, F.; Zeng, L.; Zhao, Y.; Zhao, Y.; Deng, P.; Zhong, D.; Zhu, J. K.*; Xu, H. E.*; Xu, Y*. An ABA-mimicking ligand that reduces water loss and promotes drought resistance in plants. (共同通訊)

         Cell Res, 2013, 23, 1043-1054.